Cationic and Biocompatible Polymer/Lipid Nanoparticles as Immunoadjuvants

Nanostructures have been of paramount importance for developing immunoadjuvants. They must be cationic and non-cytotoxic, easily assembling with usually oppositely charged antigens such as proteins, haptens or nucleic acids for use in vaccines. We obtained optimal hybrid nanoparticles (NPs) from the...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yunys Pérez-Betancourt, Péricles Marques Araujo, Bianca de Carvalho Lins Fernandes Távora, Daniele Rodrigues Pereira, Eliana Lima Faquim-Mauro, Ana Maria Carmona-Ribeiro
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	biocompatible polymer cationic lipid poly(methyl methacrylate) dioctadecyl dimethyl ammonium bromide hybrid nanoparticles ovalbumin Pharmacy and materia medica RS1-441
Acceso en línea:	https://doaj.org/article/81f95170bdcb4172812d96dc0662fd2a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:81f95170bdcb4172812d96dc0662fd2a
record_format	dspace
spelling	oai:doaj.org-article:81f95170bdcb4172812d96dc0662fd2a2021-11-25T18:41:14ZCationic and Biocompatible Polymer/Lipid Nanoparticles as Immunoadjuvants10.3390/pharmaceutics131118591999-4923https://doaj.org/article/81f95170bdcb4172812d96dc0662fd2a2021-11-01T00:00:00Zhttps://www.mdpi.com/1999-4923/13/11/1859https://doaj.org/toc/1999-4923Nanostructures have been of paramount importance for developing immunoadjuvants. They must be cationic and non-cytotoxic, easily assembling with usually oppositely charged antigens such as proteins, haptens or nucleic acids for use in vaccines. We obtained optimal hybrid nanoparticles (NPs) from the biocompatible polymer poly(methyl methacrylate) (PMMA) and the cationic lipid dioctadecyl dimethyl ammonium bromide (DODAB) by emulsion polymerization of methyl methacrylate (MMA) in the presence of DODAB. NPs adsorbed ovalbumin (OVA) as a model antigen and we determined their adjuvant properties. Interestingly, they elicited high double immune responses of the cellular and humoral types overcoming the poor biocompatibility of DODAB-based adjuvants of the bilayer type. The results suggested that the novel adjuvant would be possibly of use in a variety of vaccines.Yunys Pérez-BetancourtPéricles Marques AraujoBianca de Carvalho Lins Fernandes TávoraDaniele Rodrigues PereiraEliana Lima Faquim-MauroAna Maria Carmona-RibeiroMDPI AGarticlebiocompatible polymercationic lipidpoly(methyl methacrylate)dioctadecyl dimethyl ammonium bromidehybrid nanoparticlesovalbuminPharmacy and materia medicaRS1-441ENPharmaceutics, Vol 13, Iss 1859, p 1859 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	biocompatible polymer cationic lipid poly(methyl methacrylate) dioctadecyl dimethyl ammonium bromide hybrid nanoparticles ovalbumin Pharmacy and materia medica RS1-441
spellingShingle	biocompatible polymer cationic lipid poly(methyl methacrylate) dioctadecyl dimethyl ammonium bromide hybrid nanoparticles ovalbumin Pharmacy and materia medica RS1-441 Yunys Pérez-Betancourt Péricles Marques Araujo Bianca de Carvalho Lins Fernandes Távora Daniele Rodrigues Pereira Eliana Lima Faquim-Mauro Ana Maria Carmona-Ribeiro Cationic and Biocompatible Polymer/Lipid Nanoparticles as Immunoadjuvants
description	Nanostructures have been of paramount importance for developing immunoadjuvants. They must be cationic and non-cytotoxic, easily assembling with usually oppositely charged antigens such as proteins, haptens or nucleic acids for use in vaccines. We obtained optimal hybrid nanoparticles (NPs) from the biocompatible polymer poly(methyl methacrylate) (PMMA) and the cationic lipid dioctadecyl dimethyl ammonium bromide (DODAB) by emulsion polymerization of methyl methacrylate (MMA) in the presence of DODAB. NPs adsorbed ovalbumin (OVA) as a model antigen and we determined their adjuvant properties. Interestingly, they elicited high double immune responses of the cellular and humoral types overcoming the poor biocompatibility of DODAB-based adjuvants of the bilayer type. The results suggested that the novel adjuvant would be possibly of use in a variety of vaccines.
format	article
author	Yunys Pérez-Betancourt Péricles Marques Araujo Bianca de Carvalho Lins Fernandes Távora Daniele Rodrigues Pereira Eliana Lima Faquim-Mauro Ana Maria Carmona-Ribeiro
author_facet	Yunys Pérez-Betancourt Péricles Marques Araujo Bianca de Carvalho Lins Fernandes Távora Daniele Rodrigues Pereira Eliana Lima Faquim-Mauro Ana Maria Carmona-Ribeiro
author_sort	Yunys Pérez-Betancourt
title	Cationic and Biocompatible Polymer/Lipid Nanoparticles as Immunoadjuvants
title_short	Cationic and Biocompatible Polymer/Lipid Nanoparticles as Immunoadjuvants
title_full	Cationic and Biocompatible Polymer/Lipid Nanoparticles as Immunoadjuvants
title_fullStr	Cationic and Biocompatible Polymer/Lipid Nanoparticles as Immunoadjuvants
title_full_unstemmed	Cationic and Biocompatible Polymer/Lipid Nanoparticles as Immunoadjuvants
title_sort	cationic and biocompatible polymer/lipid nanoparticles as immunoadjuvants
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/81f95170bdcb4172812d96dc0662fd2a
work_keys_str_mv	AT yunysperezbetancourt cationicandbiocompatiblepolymerlipidnanoparticlesasimmunoadjuvants AT periclesmarquesaraujo cationicandbiocompatiblepolymerlipidnanoparticlesasimmunoadjuvants AT biancadecarvalholinsfernandestavora cationicandbiocompatiblepolymerlipidnanoparticlesasimmunoadjuvants AT danielerodriguespereira cationicandbiocompatiblepolymerlipidnanoparticlesasimmunoadjuvants AT elianalimafaquimmauro cationicandbiocompatiblepolymerlipidnanoparticlesasimmunoadjuvants AT anamariacarmonaribeiro cationicandbiocompatiblepolymerlipidnanoparticlesasimmunoadjuvants
_version_	1718410783318081536

Cationic and Biocompatible Polymer/Lipid Nanoparticles as Immunoadjuvants

Ejemplares similares